Cancer cell lines for drug discovery and development

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Preclinical models often lack sufficient clinical predictive power, leading to high failure rates in phase III clinical trials.
• Commonly used in vitro cell lines and xenografts may inadequately mimic human responses, impacting drug development.
• Belief in model inadequacy drives research into more sophisticated models like patient-derived xenografts.

Purpose of the Study:

• To explore the evidence driving the shift from in vitro cell lines to xenograft models for drug screening.
• To review the advantages and disadvantages of cell lines and xenografts in preclinical drug development.
• To suggest modifications to in vitro cell line use to enhance predictive capacity.

Main Methods:

• Review of existing literature on preclinical cancer models.
• Comparative analysis of in vitro cell lines and various xenograft models.
• Exploration of strategies to improve the predictive value of cell line models.

Main Results:

• Current preclinical models, including cell lines and xenografts, exhibit limitations in predicting clinical outcomes.
• Patient-derived xenografts are increasingly favored for their potential to better represent human cancer heterogeneity.
• In vitro cell line models may be adaptable to improve their predictive relevance.

Conclusions:

• The limitations of current preclinical models necessitate a critical evaluation of their use in drug discovery.
• Further research into optimizing existing models and developing novel approaches is crucial for improving drug development success rates.
• Enhancing the predictive power of preclinical models is essential to reduce late-stage trial failures and accelerate the delivery of effective therapies.